Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications

Haiming Wang, Zifan Liu, Junjie Shao, Lejian Lin, Min Jiang, Lin Wang, Xue-Chun Lu, Haomin Zhang, Yundai Chen, Ran ZhangJournal of Immunology Research 2020 · DOI

TL;DR

This review explores the intricate roles of the immune system and inflammation in the development and progression of Acute Coronary Syndrome (ACS). It highlights how an imbalance between pro- and anti-inflammatory immune responses contributes to unstable plaques and adverse cardiovascular events, emphasizing the concept of "residual inflammatory risk" (RIR) and discussing potential therapeutic strategies.

What Problem Does This Paper Address?

Acute Coronary Syndrome (ACS) remains a leading cause of death globally. While traditional risk factors like high cholesterol and blood pressure are well-established, a significant portion of ACS cases are linked to underlying inflammation. This paper addresses the complex interplay between the immune system and inflammation in the pathogenesis of ACS, particularly focusing on how dysregulation of immune networks can lead to the destabilization of atherosclerotic plaques and subsequent acute events. It also tackles the challenge of "residual inflammatory risk" (RIR) – the persistent inflammation that remains even after optimal treatment of traditional risk factors – and the need for better strategies to manage it.

Methods

This paper is a comprehensive review article. The authors synthesize and analyze existing research from a wide range of sources, including preclinical studies, clinical trials, and epidemiological data. They employ a "from bench to bedside" perspective, bridging molecular mechanisms with clinical implications and therapeutic strategies. The review draws upon evidence from various immunological assays, imaging techniques (like PET and CCTA), and clinical outcome data from major trials.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • ACS as an Inflammatory Disease: The paper strongly posits that ACS is fundamentally an inflammation-related disease, driven by complex interactions between immune cells and vascular cells.
  • The Dual Nature of Immune Networks: Both proatherogenic (promoting plaque buildup) and antiatherogenic (counteracting inflammation and promoting stability) immune networks are crucial. An imbalance, rather than the mere presence of inflammation, is key to ACS development.
  • Residual Inflammatory Risk (RIR): A significant finding is the concept of RIR, where elevated inflammatory markers (like hsCRP) persist even after standard treatments, indicating a continued risk for cardiovascular events. Managing RIR is presented as a critical unmet need.
  • Plaque Instability Mechanisms: The review details how immune cells, particularly macrophages and T cells, contribute to plaque rupture through mechanisms like matrix metalloproteinase (MMP) production and the destabilization of fibrous caps.
  • Therapeutic Potential of Targeting Inflammation: Clinical trials like CANTOS, COLCOT, and LoDoCo have shown promise in using anti-inflammatory therapies to reduce cardiovascular events, validating the importance of targeting RIR.
  • Challenges in Therapeutic Development: Despite promising preclinical data, translating anti-inflammatory therapies into widespread clinical success has been challenging, with some trials yielding negative or contradictory results. This highlights the complexity of the immune system and the need for precise targeting.

Key Results

  • CANTOS Trial: Demonstrated that canakinumab (an IL-1β inhibitor) significantly reduced major adverse cardiovascular events (MACE) in ACS patients with elevated hsCRP, independent of lipid-lowering therapy.
  • COLCOT and LoDoCo Trials: Showed that colchicine, an anti-inflammatory drug, could lower the risk of cardiovascular events in patients with coronary artery disease and ACS, respectively.
  • RIR Prevalence: Nearly 60% of ACS patients exhibit high hsCRP levels, signifying a substantial residual inflammatory risk.
  • Immune Cell Roles: Macrophages (especially M1 type) and specific T cell subsets (like CD4+CD28null T cells) are implicated in promoting plaque rupture, while M2 macrophages and regulatory T cells (Treg) play antiatherogenic roles.

Limitations and Future Work

  • Complexity of Immune Regulation: The paper acknowledges the intricate balance required between proatherogenic and antiatherogenic immune responses. Simply suppressing inflammation might not be sufficient and could lead to adverse effects like increased susceptibility to infections.
  • Translational Challenges: Many promising anti-inflammatory agents that show efficacy in animal models fail to translate into significant clinical benefits in humans. This is attributed to factors like the difficulty in timing drug administration and the limitations of current experimental models.
  • Need for Better Biomarkers: Identifying patients who would benefit from anti-inflammatory therapy remains a challenge due to the lack of precise biomarkers for RIR. The paper suggests that integrating imaging techniques like CCTA with inflammatory markers (CRP, FAI) could improve risk stratification.
  • Future Directions: The authors advocate for personalized medicine approaches, focusing on restoring the balance of immune regulation rather than just suppressing inflammation. This includes exploring Treg cell-based therapies and developing more targeted antiatherogenic adjuvant strategies. Further research is needed to understand the precise roles of various T cell subsets and to refine therapeutic targets.

Summary updated

Abstract

Acute coronary syndrome (ACS) is a major cause of acute death worldwide. Both innate and adaptive immunity regulate atherosclerosis progression, plaque stability, and thrombus formation. Immune and inflammation dysfunction have been indicated in the pathogenesis of ACS. The imbalance in the proatherogenic and antiatherogenic immune networks promotes the transition of plaques from a stable to unstable state and results in the occurrence of acute coronary events. The residual inflammatory risk (RIR) has received increasing attention in recent years, and lowering RIR has been expected to improve the outcomes of ACS patients. The CANTOS, COLCOT, and LoDoCo trials verified the benefits of reducing cardiovascular events using anti-inflammation therapies; however, most of the other studies focusing on lowering RIR produced negative or contradicting results. Therefore, restoring the balance in autoimmune regulation is essential because proatherogenic and antiatherogenic immunomodulatory effects are equally important in the complex human immune network. In this review, we summarized the recent evidence of the roles of proatherogenic and antiatherogenic immune networks in the pathogenesis of ACS and discussed how immune and inflammation contribute to atherosclerosis progression, plaque instability, and adverse cardiovascular events. We also provide a "from bench to bedside" perspective of a novel and promising personalized strategy in RIR intervention and therapeutic approaches for the treatment of ACS.
BibTeX
@article{wang2020immune,
  author = {Haiming Wang and Zifan Liu and Junjie Shao and Lejian Lin and Min Jiang and Lin Wang and Xue-Chun Lu and Haomin Zhang and Yundai Chen and Ran Zhang},
  title = {{Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications}},
  journal = {Journal of Immunology Research},
  year = {2020},
  doi = {10.1155/2020/4904217},
}
Figure